ArticleHaematologica2018

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.

Giovanni Cazzaniga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.